Share Talk LTD

Share Talk LTD

Designed for Private - Retail Investors, bloggers, brokers, PR, listed companies to communicate on one information portal. Please note we are an unregulated website and will never give out advice. We are here to make investing a level playing field.

  1. Zak Mir interviews Poolbeg Pharma’s CEO Jeremy Skillington & Principal Scientist Liam Tremble

    5 DAYS AGO

    Zak Mir interviews Poolbeg Pharma’s CEO Jeremy Skillington & Principal Scientist Liam Tremble

    Poolbeg Pharma PLC (AIM: POLB, OTC: POLBF) Chief Executive Officer Jeremy Skillington and Principal Scientist Liam Tremble talked with Share Talk's Zak Mir about the company’s conference season. We recently returned from a busy conference season and wanted to share the main messages, progress and next steps for POLB001 and our oral GLP-1 programme. Between ESMO in Berlin and BioEurope in Barcelona, we gained clinical insights, interest in partnering, and clarity on trial design as we prepare for a phase 2A CRS prevention trial and a proof-of-concept study for oral GLP-1. Please see the questions for the interview: You recently attended the ESMO conference. Can you give us an overview of the conference – Liam Did you discuss POLB 001 at ESMO, and what was the general feedback? – Liam What were the key takeaways from the conference itself? – Liam Which leads me onto you, Jeremy, you just returned from BIO-Europe, how was the conference, and how do your current programmes, such as POLB 001 and your Oral GLP1 position itself, stand out at this partnering conference? - Jeremy BIO-Europe is all about connections. What types of partnerships are you seeking this year? You recently announced a collaboration with ACT to conduct your upcoming POLB 001 Phase 2a trial —so why attend the conference? Jeremy Is conference season over? Jeremy & Liam Conference calendar and next events The autumn run is not over. After BioEurope we planned continued follow ups at London Health Innovation Week and then the very significant ASH meeting in early December in Orlando. ASH is the major haemato‑oncology event where big pharma present emerging data and where clinical teams, investigators and partners congregate. We also have JP Morgan and other investor events on the horizon into the new year.

    15 min
  2. Zak Mir talks to Paul Mathieson, CEO of Amazing AI Plc

    6 NOV

    Zak Mir talks to Paul Mathieson, CEO of Amazing AI Plc

    Zak Mir talks to Paul Mathieson, CEO of Amazing AI, in the wake of the global fintech group, which has a Digital Asset Treasury Policy that provides online consumer loans and AI finance-related services. AAI announces that, via its 100% owned Mauritius subsidiary Amazing AI Services Ltd, it has made its initial, small and non-material purchase of digital assets within its Digital Asset Treasury as part of a strategic implementation test. Amazing AI plc (AQSE: AAI) has taken its first step into digital assets, confirming that its subsidiary Amazing AI Services Ltd has established a Digital Asset Treasury with an initial Bitcoin acquisition valued in the low four-figure USD range. The company said it will use a dollar-cost averaging strategy to build its position and plans to expand its holdings to include Ethereum, XRP, and Solana before the end of December 2025. Amazing AI is also exploring the addition of a fifth digital asset, potentially gold-backed, as part of a broader diversification strategy. Management said the company intends to increase its overall exposure to digital assets through selective acquisitions while continuing to prioritise its core artificial intelligence operations. Paul Mathieson, CEO of Amazing AI plc said, “We are excited to have made our initial purchase in our Digital Asset Treasury. We believe that AAI’s strategy is Digital Asset Treasury 3.0, aiming to provide greater upside whilst insulating Amazing AI from downside exposure across a diversified basket of leading digital assets. By being patient and strategic we have avoided the recent significant price correction in digital assets.”

    11 min
  3. Zak Mir Speaks with Stafford Masie and Warren Wheatley of Africa Bitcoin Corporation

    25 OCT

    Zak Mir Speaks with Stafford Masie and Warren Wheatley of Africa Bitcoin Corporation

    Zak Mir talks to Stafford Masie, Executive Chairman, and Warren Wheatley, CEO, Africa Bitcoin Corporation, which is set to list on the Aquis Exchange. I sat down with Stafford Maisy, Executive Chairman, and Warren Wheatley, CEO of Africa Bitcoin Corporation to understand how a South African financial services group plans to combine an established SME lending business with a Bitcoin treasury strategy. What follows is a clear view of their thesis, the mechanics behind the plan, and why they believe Africa is the ideal place for a Bitcoin-first corporate treasury. What is Africa Bitcoin Corporation? Africa Bitcoin Corporation is the first publicly listed company in Africa to adopt Bitcoin as a core treasury asset. The business started as a financial services group focused on secured lending to small and medium enterprises across South Africa and has now announced a strategic pivot: use Bitcoin to strengthen the balance sheet, access cheaper global capital, and scale lending and impact across the continent. Bitcoin was made for us. That tagline captures their conviction. Stafford and Warren describe Bitcoin not as a speculative novelty but as a practical, life-changing instrument in African markets where currency debasement and weak rails make reliable stores of value precious. They are positioning ABC to be the regulated, listed vehicle that gives African investors, citizens and institutions exposure to Bitcoin in a jurisdictional, compliant manner. Why a Bitcoin treasury strategy in Africa? The argument is straightforward and rooted in local economic realities: Demand is pent up. In many African countries access to Bitcoin is restricted, exchanges are nascent, and investors lack regulated entry points. Currency debasement makes a fixed-supply, globally recognised asset attractive as a store of value. Bitcoin is being used as a medium of exchange in sub-Saharan Africa at higher rates than almost anywhere else. Merchant acceptance and day-to-day use are significant. The informal economy is large, sophisticated and largely cash based. Creating rails to bring informal participants into regulated Bitcoin exposure is an opportunity to increase financial inclusion. They point to examples like Namibia, where ABC has already completed a dual listing, as evidence of demand for a regulated way to gain Bitcoin exposure across the continent. How the strategy works in practice ABC’s plan is not just to buy Bitcoin and sit on it. The stated objective is to increase Bitcoin per share over time by using Bitcoin as pristine collateral to unlock cheaper capital globally and then deploy that capital into secured, high-impact lending within Africa. Key mechanics include: Bolster the balance sheet by holding Bitcoin as a core asset, increasing the company’s creditworthiness. Borrow in deep capital markets such as Japan, Switzerland or the US at single-digit interest rates. On-lend to African SMEs at materially higher rates, creating an interest-rate arbitrage that can be accretive to shareholders and increase Bitcoin per share. Warren explained the arbitrage clearly: borrow at around 6 to 9 percent in developed markets and on-lend in Africa at roughly 20 to 22 percent, resulting in a margin that can be reinvested into the treasury strategy and into the core lending book. Lending model and impact ABC’s lending is secured and targeted at businesses rather than microfinance. Typical loan sizes are between £100,000 and £1,000,000, and the company has a three-year track record of deploying such loans. This is presented as high-impact lending: Stafford noted the social multiplier effect — for every modest amount deployed, jobs are created. The combination of secure lending with a Bitcoin-backed balance sheet is intended to simultaneously deliver financial returns and measurable local impact. Regulation, listings and rollout across Africa ABC’s listing strategy begins with the Johannesburg Stock Exchange as its home market and has expanded with a dual listing in Namibia. The company plans further listings in five other sizable African markets to create regulated access points for citizens where Bitcoin cannot easily be bought today. Key points on compliance and execution: Using the Johannesburg Stock Exchange as the regulatory anchor simplifies subsequent listings because many African exchanges accept a fast-track process that recognises the rigor of JSE scrutiny. Additional listings are described as access points, not liquidity hubs. Deep liquidity is expected to come from listings on major markets such as London, Frankfurt and the US. ABC argues that South Africa offers the best combination of liquidity, governance and integration with global capital markets, giving the company a practical moat for a continental rollout. Why ABC believes it can be the dominant player Stafford and Warren set out several competitive advantages: They bring on-the-ground experience across African townships and informal economies, not just a financial services pedigree. Their lending business is naturally synergistic with a Bitcoin treasury. The balance sheet amplification unlocks cheaper capital which scales the lending model. They claim a governance and regulatory network, including relationships with the South African Reserve Bank and the JSE, that many competitors lack. They also stressed differentiation from other companies that have taken on Bitcoin treasuries without an operational fit. Unlike firms that can only announce a holding, ABC intends to actively use Bitcoin as collateral to build a repeatable, accretive business model. Our sole objective is continuously and perpetually to increase Bitcoin per share. Practical concerns and responses Addressing obvious questions, Stafford explained that cross-border expansion can be managed without an explosion in compliance costs because partner exchanges usually accept the JSE’s due diligence and offer a fast-track listing. The company will still meet KYC and AML checks locally, but the model is designed to be operationally manageable. On the human side, both leaders emphasised their township roots and the reality of local economies. They challenged western misperceptions about African economies, arguing that informal cash markets are sophisticated and primed for the benefits Bitcoin can bring when offered through regulated, understandable rails. What to watch next Key milestones to monitor include: Final listing on the Aquis Exchange and subsequent planned listings across African markets. Announcements about the size and timing of initial Bitcoin purchases for the treasury and the financing structures used to leverage that collateral. Rollout of lending products that blend fiat and Bitcoin exposure, such as hybrid instruments or "bit bonds", which the company mentioned as a way to grow the treasury without causing dilution. Partnerships with deeper capital markets to provide liquidity and enable the interest-rate arbitrage at scale. Conclusion Africa Bitcoin Corporation presents a thesis built on a credible underlying business, continental demand, and a conviction that Bitcoin offers more than speculative upside in African markets. By using Bitcoin as pristine collateral to access global liquidity and scale secured lending locally, ABC aims to be both accretive for shareholders and transformational for customers on the ground. Whether you view Bitcoin as a speculative asset or as money, ABC’s approach is pragmatic: use the asset to create real economic value, deliver credit to businesses that need it, and increase Bitcoin exposure for investors and citizens who currently lack regulated access. For those tracking the intersection of crypto, emerging markets and impact finance, this is a story to follow closely.

    19 min
  4. Zak Mir talks to Dr Kerim Sener, Managing Director of Ariana Resources Plc

    30 SEPT

    Zak Mir talks to Dr Kerim Sener, Managing Director of Ariana Resources Plc

    Zak Mir talks to Dr Kerim Sener, Managing Director of Ariana Resources, in the wake of the recent summary of projects with drilling planned at Dokwe and the dual listing on the ASX. Highlights: o  Ariana commenced trading on the ASX on 10 September 2025, following the completion of a A$11 million IPO, capitalising the Company at c.A$72.5 million. o  Flagship >1Moz Dokwe Gold Project in Zimbabwe continues to be advanced through its Definitive Feasibility Study ("DFS"), as additional technical consultancy companies are appointed. o  Drilling companies have submitted tenders to undertake a significant new diamond and Reverse Circulation ("RC") drilling programme of c.11,000m at Dokwe; with contracts due to be awarded imminently and drilling to commence in early October. o  The drilling programme is designed to substantially increase the current 1.4Moz Resource and 0.8Moz Reserve (as defined in the Pre-feasibility Study - "PFS") at Dokwe, while also providing additional technical data for the DFS. o  Gold-silver production continues from the Turkish operations (held 23.5% by Ariana), with production from the Tavşan Mine due to be augmented through its heap-leach imminently. Dr. Kerim Sener, Managing Director, commented: "The successful dual-listing of Ariana on the ASX and its associated capital raising of A$11 million, is a landmark moment since first listing on AIM in 2005. In that time, the Company has evolved from a greenfield exploration company to a gold producer. "The ASX listing provides a powerful platform for us to accelerate our growth strategy, broaden our investor base, and unlock the full potential of our asset portfolio. Central to this is the 100% owned Dokwe Gold Project in Zimbabwe, a highly compelling development opportunity with significant scale, strong economics and exciting upside potential. "With a gold price currently exceeding US$3,600/oz the Company continues to optimise the path forward for the fast-track development of Dokwe, deploying all our skills and capabilities to build up a planned annual gold production of at least 60,000 ounces of gold per annum over a thirteen-year mine life, based on the PFS. With a proven track record of discovery and delivery, Ariana is well positioned to continue building a long-term, sustainable and globally recognised gold company."

    14 min
  5. Zak Mir talks to Paul Mathieson, CEO of Amazing AI

    24 SEPT

    Zak Mir talks to Paul Mathieson, CEO of Amazing AI

    Zak's Traders Cafe sat down with Paul Mathieson, CEO of Amazing AI, to unpack a fresh take on corporate crypto exposure — a strategy Paul describes not just as "Bitcoin treasury 2.0" but as crypto treasury 3.0. After a turbulent few months for London-listed companies that rushed to add Bitcoin to their balance sheets, Paul and I discussed why the old model is breaking down and how his team plans to approach things differently: more sophisticated, more diversified, and better protected. Why the Bitcoin Treasury 1.0 model is fading Earlier this year many companies followed a simple playbook: raise equity, buy Bitcoin, and hold it on the balance sheet. That headline-friendly approach produced big share price moves in May–July, but many of those gains have since evaporated — some names are down as much as 80% from their peaks. Investors and markets reacted; hype cooled. As Paul put it, the straightforward buy-and-hold crypto treasury is "pretty simple" and increasingly seen as outdated. The problem with buy-and-hold Heavy dilution: companies raising repeatedly to buy more crypto. Binary exposure: full directional risk to a single asset like Bitcoin. Market expectation vs operational reality: investors began pricing in the flaws once the euphoria passed. Introducing Crypto Treasury 3.0: a different philosophy Paul argues Amazing AI is moving beyond the one-dimensional treasury model by combining derivatives expertise, diversification across crypto assets, active risk management, and a profitable underlying business to fund the strategy. As Paul told me: "I don't think it's just crypto treasury 2.0. I think it's actually 3.0. We are going beyond the basic to diversify... and more importantly managing the exposure, not just sitting there." — Paul MathiesonKey pillars of the approach: Derivatives-based exposure: using long-dated options and futures to gain leveraged crypto exposure while defining downside risk. Diversification: exposure spread across multiple crypto assets rather than a single-asset bet. Active management: protective hedges and re-protection on the way up to lock in gains. Revenue backing: a core U.S. lending business generating strong cash flows to fund option premiums and operations. Opportunistic M&A: potential acquisitions of failed "crypto 1.0" players to consolidate and repurpose assets. How the derivatives strategy works — plain English Paul drew on decades of funds management and investment banking experience to adopt option structures that can deliver asymmetric returns. The approach is not simply selling covered calls (income-focused), but more like a strangle strategy combined with targeted protection. Strangle-like positions: buying combinations of calls and puts to profit from large moves either up or down. The structure benefits from volatility and large directional moves. Defined downside: losses are limited to the premiums paid for options, rather than the full exposure of owning the underlying crypto outright. Leverage potential: relatively small cash outlay on options can create very large notional exposure (Paul discussed scenarios of up to 100x notional exposure in upside cases), while premium cost caps the downside. Paul emphasised that the firm is comfortable paying option premiums because Amazing AI has a core business able to generate predictable revenue. That changes the math: instead of raising equity constantly to buy more crypto, small capital raises can create sizable market exposure via derivatives. Backtest results and credibility Paul shared that he backtested his strategy over two decades and, in his words, it "never lost money" and averaged around 500% returns historically, with larger gains on upside moves. He also said the approach underpins the holdings of long-term shareholders in the company today. While past performance and backtests are not guarantees, the claim signals the firm has applied a rigorous, experience-led framework rather than relying on speculation alone. Differences from covered-call or simple buy-and-hold strategies When I asked whether the approach is similar to covered-call income strategies, Paul was clear: it's materially different. Covered calls generate income by selling upside, moderating upside participation in exchange for premiums. Amazing AI’s method is designed to benefit from significant directional moves while protecting capital via paid protection. Covered call = sell upside to earn premium, capped upside. Strangle/option approach = pay premium for asymmetric exposure and defined loss, large upside potential if volatility or direction materialises. Operational advantages: less dilution, more optionality One of the practical benefits Paul highlighted is capital efficiency. Because option premiums are significantly smaller than buying the underlying outright, Amazing AI can achieve large crypto exposures from comparatively modest raises. Paul also noted he remains the major shareholder and is not interested in frequent dilution, aligning management incentives with long-term shareholders. Additional operational levers include: Using revenues from a U.S. lending arm (quoted rate: 59.9% on loans) to fund premium payments and operations. Rolling and re-protecting positions as markets move to lock in gains and manage risk. Purchasing distressed "crypto 1.0" assets or companies and converting their strategy to the new model. Risk considerations and why diversification matters Paul stressed that while he believes in crypto, prudent risk management matters. He mentioned edge-case risks — for example, quantum attacks or specific vulnerabilities in mining — as reasons to diversify beyond Bitcoin alone. The goal is to construct a portfolio where only a subset of holdings needs to perform for the strategy to succeed. In short: rather than bet everything on a single outcome (Bitcoin to infinity or to zero), the approach seeks multiple asymmetric bets and defined downside exposure. What to watch next Over the coming months investors should watch how Amazing AI implements the strategy: the mix of option structures used, the degree of leverage taken, how the company re-protects gains as markets rise, and whether opportunistic acquisitions materialise. Also worth monitoring will be capital raises and how management balances funding the strategy with shareholder dilution. Conclusion The landscape for corporate crypto treasuries has shifted. Simple buy-and-hold has shown vulnerabilities in a choppy market. Amazing AI’s approach, as explained by Paul Mathieson, blends derivatives expertise, diversification, active hedging, and an operating business that helps fund premiums — an attempt to deliver asymmetric upside while capping downside. If you’re interested in corporate crypto strategies or the evolving ways companies are gaining exposure to digital assets, this is a model worth watching: it’s about turning raw crypto exposure into a more manageable, capital-efficient, and actively managed program. Disclaimer & Declaration of Interest: The information, investment views, and recommendations in this Zaks Traders Cafe interview are provided for general information purposes only. Nothing in this interview should be construed as a promotion or solicitation to buy or sell any financial product relating to any companies under discussion or referred to or to engage in or refrain from doing so or engage in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the commentator but no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion.

    10 min
  6. Zak Mir talks to Charles Dickson, CEO of Roadside Real Estate

    17 SEPT

    Zak Mir talks to Charles Dickson, CEO of Roadside Real Estate

    We spoke with Charles Dixon, CEO of Roadside Real Estate, to unpack the company's latest moves: a strategic disposal, operational hires and an explicit push into the energy forecourt/roadside retail sector. The conversation covered why the group is simplifying its balance sheet, how the team is being strengthened, and what investors should watch for next. Important note: Nothing in this article is investment advice. The conversation covered company strategy and balance sheet items, and Charles and others may hold positions in the shares discussed. Always do your own research before making any investment decisions. What just happened: disposals to simplify the business Roadside continues to streamline its portfolio to concentrate on the roadside retail and operational opportunity. Two disposal-related items are central: In June the group announced a deal to sell the remainder of the Cambridge Sleep Sciences estate for approximately £48 million. More recently the company announced the proposed disposal of 100% of its Commercial Property business to Tarncourt Properties Limited for an agreed price of approximately £12 million, resulting in a net consideration receivable of about £4.7 million. Charles explained the rationale plainly: these sales further simplify the equity story, increase cash on the balance sheet and free up resources to accelerate acquisitions in the roadside retail operational space. “...putting more cash on balance sheet, and increasing our resources for acquisitions in the roadside retail operational space.”Sharpening the management team: experience to execute Execution is a major focus. Roadside has been beefing up its operational bench with senior retail and roadside experience: David Philpot has been appointed COO. He joins from running BP/M&S’s European roadside operations — a business of roughly 3,500 sites — and previously worked at Marks & Spencer running their franchise business. Steve Carson joined in May as non-exec chair. Steve brings about 30 years of retail experience including senior roles across Sainsbury’s, Argos, Holland & Barrett and SCS. Charles described David’s arrival as a "big win" given his direct, relevant experience. As I put it during the interview: you could almost picture him wearing a Roadside Real Estate T‑shirt — the fit is that natural. First acquisition and the operational plan Roadside has already completed a first acquisition under the refocused strategy. The company purchased a former petrol filling station in Coventry. The plan is to reinstate the site, build a substantially larger retail shop on the forecourt and re-open next year. Beyond that single deal, Charles was clear about the acquisition playbook: Roadside wants to buy both the property and the operating business. The target sub-sector is the energy forecourt/roadside retail market — a highly fragmented, overlooked category that can deliver attractive returns when consolidated and professionally operated. Expect pace: Charles indicated the group is evaluating multiple businesses and anticipates acquiring three to four businesses over the next 12 months as Roadside scales its operational footprint. Funding the roll-up: cash, bank facilities and measured leverage Funding for the buy-and-operate strategy will be a mix of existing cash and bank facilities. Key points Charles shared: Roadside now has strong cash resources — over £50 million available. They also have access to banking facilities and expect lenders to be receptive; banks like the roadside sector because security is solid, delinquency is low and cash flows are predictable. That said, the company intends to use leverage sensibly. Charles emphasised a cautious approach: “We’re not looking to overlever ourselves.” Valuation, ownership and what investors should think about Charles is the company’s largest shareholder, controlling around 30% of Roadside directly and indirectly. He increased his position in May with what he described as one of the larger direct buys in the market this year. He also offered a straightforward way to look at valuation: strip out cash from the market capitalisation to see the underlying operating valuation. From his perspective, when you take that cash off the market cap, Roadside still looks cheap and there is further upside to come. Recent share performance: last year the stock rose over 300%, and year-to-date it was nearly up 100% at the time of our conversation. Charles said he expects further share price growth over the coming months as the business executes its strategy. “I control around 30% of the company directly and indirectly... take off our cash from our market cap and then look at our actual underlying market cap and we're very, very cheap still.”Why the roadside/forecourt sector appeals The sector ticks several boxes that make it attractive for consolidation and operational improvement: Highly fragmented: many small operators create opportunities for roll-up scale benefits. Operational upside: better retailing on forecourts and improved shop formats can meaningfully increase returns. Bank-friendly cashflows: predictable, secure income streams that lenders understand and are willing to finance. What to watch next Key near-term items for investors and observers: Announcements of additional acquisitions — Charles expects three to four deals in the next 12 months. Progress on the Coventry site reinstatement and re-opening next year. How the company deploys the proceeds from the Cambridge Sleep Sciences and Commercial Property disposals. Any updates on financing and the level of leverage used for acquisitions. Conclusion Roadside Real Estate has moved decisively from being a mixed-asset property group toward a focused, buy-and-operate roadside retail business. The disposals clear the path, the balance sheet is stronger, and the hires bring the operating expertise needed to scale. If the team can execute on the planned roll-up of forecourt operators, the impact on returns and the equity story could be material. If you want the full discussion, watch my interview with Charles Dixon for the direct comments and context. I’ll be keeping an eye on the next acquisitions and operational milestones — this is a story that should move quickly from here. Disclaimer & Declaration of Interest: The information, investment views, and recommendations in this Zaks Traders Cafe interview are provided for general information purposes only. Nothing in this interview should be construed as a promotion or solicitation to buy or sell any financial product relating to any companies under discussion or referred to or to engage in or refrain from doing so or engage in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the commentator but no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion.

    6 min
  7. Zak Mir Speaks with Fiinu CEO Dr. Marko Sjoblom on New Strategic Partnership

    16 SEPT

    Zak Mir Speaks with Fiinu CEO Dr. Marko Sjoblom on New Strategic Partnership

    Zak Mir caught up with Dr. Marko Sjoblom, Chief Executive Officer of Fiinu Plc, as the fintech company unveiled a major milestone in its growth journey. Fiinu has announced an exclusive strategic partnership with Conister Bank Limited, a subsidiary of Manx Financial Group, to bring its innovative Plugin Overdraft® product to the UK market. The partnership marks a significant step forward for Fiinu as it works to deliver a new kind of overdraft solution, designed to provide greater flexibility and accessibility to UK consumers. Why this matters: unbundling a 300-year-old product At first glance an overdraft might seem mundane — it’s a feature that’s been around for centuries. What Fiinu is attempting, however, is anything but ordinary. Dr. Sjoblom described the Plugin Overdraft® as “very revolutionary,” and with good reason: it unbundles a credit product traditionally tied to a bank account and makes it available independently to consumers through partner banks. Having worked on overdraft-style products in the UK for 15 years, Marko emphasized that once people understand what the Plugin Overdraft® does, the reaction is strong. The product is designed to be flexible, widely accessible and to be offered through partner banks rather than requiring Fiinu itself to operate as a full retail bank in the traditional sense. The Conister partnership — why it was chosen Fiinu announced an exclusive strategic partnership with Conister Bank to roll out the Plugin Overdraft® in the UK. Marko highlighted several reasons Conister is an ideal launching partner: They are nimble and able to move quickly. They have a long track record (90 years) and a credible retail presence. They already support products and customer bases that Fiinu can initially target — for example, Conister’s group-level payment products with over one million retail customers. The arrangement lets Fiinu present the product as “Conister Bank’s plug-in overdraft powered by Fiinu,” combining Conister’s regulated interface with Fiinu’s technology stack. Fiinu claims technical access to a very large potential market: they can already reach tens of millions of UK bank accounts and — via other banking partners — access up to 95% of Eurozone bank accounts. The immediate rollout will focus on Conister’s customers before scaling more broadly. Timing and next steps On timing, the plan remains to launch the product in Q4, and Fiinu is “still on track for that.” Marko described the team as finalizing the last pieces ahead of rollout. He also expects a steady stream of news as partnerships and deployments progress. From regulatory setback to a new start Fiinu’s recent history includes a painful regulatory episode. After an extended engagement with the UK regulators, the company had to surrender its bank licence in 2023 — a tough moment that prompted a strategy reset through 2024. Marko walked me through the regulatory journey in more detail: Securing a restricted licence in 2022 required a multiyear process (around 5½ years). Following that, Fiinu entered a mobilization period (the standard 12‑month window) with 19 conditions to satisfy before exiting mobilization. Fiinu met 18 of the 19 conditions; the single outstanding item related to capital requirements, and they ultimately failed on that point. Despite the licence surrender, independent audits showed Fiinu’s technology platform was robust and ready for production — a backbone for the current Conister deal. Regulation remains strict for a reason: licences allow firms to accept deposits and lend, with potential taxpayer exposure if things go wrong. Marko is supportive of the regulator’s role even as he acknowledges the process is demanding (filings for the bank licence ran to some 4,000 pages, with the mobilization creating another ~2,500 pages). Market reaction and Fiinu’s outlook Market sentiment toward Fiinu has swung dramatically. Marko noted the share price has risen roughly 3,200% year‑to‑date — a swing he attributes in part to the market having “written the company off” earlier. He framed the current position as the company rising “like the phoenix from the ashes.” He also shared a personal benchmark: a three‑year price target of 110 (his internal bonus plan target), while current levels are around 15. That comment signals considerable upside expectations from management, assuming execution and market conditions remain favourable. What makes the Plugin Overdraft® commercially attractive? A few elements combine to make the Plugin Overdraft® potentially lucrative: It addresses an underserved market left behind by high street banks that have retreated from certain forms of credit. It is integrated with partner banks’ distribution channels, allowing rapid scaling without Fiinu having to be the primary retail bank in every market. Fiinu’s technology is positioned as a white‑label or “powered by” solution that partners can adopt quickly. Marko’s assertion is simple: once customers and partners understand the product’s mechanics, adoption should follow — and that’s where the revenue opportunity lies. Regulation, fintech challengers and lessons learned We touched on comparisons with other challenger banks and fintechs that have struggled with regulators. Marko’s view is measured: yes, the entry bar is high, but that’s appropriate given the public interest in deposit safety. While the process is cumbersome and demanding, the outcome — a strong regulatory regime and careful licensing — protects consumers and the wider financial system. ""The barrier of entry is very high in the banking perimeter, but it's for a reason because ultimately they give you a license to take deposits and lend that money out."" Conclusion — why to watch Fiinu now Fiinu has navigated a difficult regulatory reset and come out with a clear path to market: a technically validated platform and a strategic distribution partner in Conister Bank. The Plugin Overdraft® is positioned as a unique product that unbundles an entrenched banking service, and the plan to launch in Q4 will be the first public test of that thesis. For investors, partners and fintech watchers, the key things to monitor over the coming months are: Execution of the Conister rollout and early consumer uptake. Further partnerships and geography expansion, especially into Europe. Regulatory developments or new licensing milestones that might expand Fiinu’s direct capabilities. Market reaction as actual product metrics (customers, usage, revenues) start to appear. If you follow fintech and embedded finance, Fiinu’s next few quarters will be telling: they’re moving from development and compliance to distribution and revenue. That shift — if executed well — could validate the Plugin Overdraft® as a genuinely disruptive product in personal credit.

    8 min
  8. Tim McCarthy, Chief Executive Officer of ImmuPharma PLC talks to Zak Mir

    12 SEPT

    Tim McCarthy, Chief Executive Officer of ImmuPharma PLC talks to Zak Mir

    Zak Mir talks to Tim McCarthy, CEO of Immupharma, the speciality biopharmaceutical company that discovers and develops peptide-based therapeutics, announcing the filing of a groundbreaking new patent application for its lead asset, P140, the world’s first “Immunormalizer.” The three discoveries that reset the strategy Under-dosing: The team concluded the dose used in the Phase III trial was far too low — roughly 10 to 15 times lower than the dose they now believe is required to achieve the intended biological effect. Steroid confounding: Standard-of-care steroids given to patients in the trial suppress the immune system and masked P140’s effect. Future trials will include steroid tapering protocols so the drug’s impact isn’t obscured. Patient stratification — “super responders”: For the first time the team identified a patient profile that responds exceptionally well to P140. That diagnostic signature is central to the patent and allows the drug to be matched to the right patients. What P140 actually does — the Immunormalizer concept Tim described P140 as an agent that restores immune homeostasis rather than suppressing the immune system. That’s an important distinction: Most current therapies try to blunt or suppress immune activity (e.g., steroids or many immunomodulators), which can cause side effects and still leave patients vulnerable. P140 appears to "normalize" the immune response — increasing or decreasing components such as B cells toward a healthy balance depending on what the patient needs. In practice that means if a patient has excessive B-cell activity, P140 reduces it; if a patient has deficient activity, P140 can boost it — a balancing action not commonly seen in current treatments. "“We’ve coined the phrase ‘Immunormalizer’ — it brings the immune system back to normal homeostasis rather than simply suppressing it.”" Safety profile that matters Across preclinical studies, Phase I/II and the Phase III programme, P140 demonstrated an unusually clean safety record: no serious adverse events and very few side effects. Tim highlighted this as a major reason the team pursued the diagnostic-plus-therapeutic patent: a safe mechanism that can be targeted precisely. The diagnostic: identifying “Type M” immune disorder patients and super responders One of the most exciting elements of the patent is the combination of a diagnostic test with the therapeutic. The diagnostic identifies patients with what ImmuPharma calls a “Type M” immune disorder — those who are likely to be super responders to P140. This stratification means future clinical trials will enroll patients who have the biomarker profile most likely to benefit, improving the chance of clear, positive outcomes. The diagnostic is precise enough that it could identify at-risk patients even before symptoms appear, enabling earlier intervention. Tim suggested it could potentially be incorporated into routine health checks, allowing doctors to pick up vulnerability to autoimmune disease much earlier than current practice permits. "“We can identify those patients that are responding to P140 and identify them as the Type M patients before they’re even getting the disease.”" Clinical path forward: higher doses, steroid tapering, targeted enrolment Building on the three discoveries, the next clinical plan is straightforward: Use higher dosing (10–15× what was used previously) to reach therapeutic exposure. Incorporate steroid tapering in trial protocols to avoid immune suppression masking the drug’s effect. Enroll biomarker-positive “Type M” patients (super responders) to maximise the chance of demonstrating efficacy. These changes address the confounders that affected the earlier trial and are supported by additional preclinical work that underpinned the patent filing. From lupus to a broad autoimmune opportunity Although P140’s clinical history has focused on lupus, Tim explained the mechanism is broadly applicable across autoimmune diseases — there are around 50 recognised autoimmune conditions. The key is that within each disease there are subsets of patients who match the Type M profile and may respond to P140. That opens a large commercial and clinical opportunity: diagnose earlier, treat the right patients, and potentially prevent disease development. Tim compared the potential impact to other recent transformative therapies in adjacent areas — stressing that the market opportunity and patient benefit could be enormous. Commercial strategy: partners, patents and deals ImmuPharma’s plan is to partner with larger pharma companies for development and global reach. Tim said discussions with multiple big pharma partners were already underway prior to the patent filing and that the patent has catalysed deeper interest. Filing the patent helps validate the science for prospective partners and allows confidential due diligence to proceed. Tim expects deals (or multiple deals) to be closed before the end of the year, saying that talks are advanced and partners recognise the uniqueness of this technology. Big pharma has been actively seeking assets in autoimmunity; an asset that combines a precise diagnostic with a safe, disease-normalizing therapeutic is particularly attractive. Where ImmuPharma stands financially Tim confirmed that cash is not an immediate concern. A recent exercise of warrants brought additional funds into the company, and he expects partner deals to provide substantial commercial funding moving forward. He said the company is comfortably funded into the second half of next year and is focused on closing partnership deals to accelerate development. How the team feels — the CEO’s perspective After years of internal restructuring, new leadership, and focused scientific work, Tim was candid about the excitement in the team. On a 1–10 scale he jokingly put himself at an 11, reflecting the belief he and the team have in the uniqueness and transformative potential of P140. "“I’ve been in this business a long time, and I’ve never been in this position… this is absolutely unique.”" Key takeaways P140 is now positioned as an “Immunormalizer” that restores immune balance rather than suppressing it. The newly filed patent covers both a precise diagnostic and the therapeutic use, enabling targeted treatment of “Type M” patients (super responders). Past Phase III results are being reinterpreted: dose was too low, steroids confounded outcomes, and patients were not stratified. Next clinical steps include higher dosing, steroid tapering, and biomarker-based patient selection. ImmuPharma expects partnership discussions to convert into deals before year-end; cash position is secure for now. If validated clinically, P140 could be transformative across many autoimmune diseases and could even be used proactively to prevent disease in at-risk individuals. Final thoughts The combination of a novel mechanism, a strong safety profile, and a companion diagnostic makes ImmuPharma’s P140 a story worth following. If the team’s scientific conclusions hold up in controlled trials with the new dosing and patient selection strategy, P140 could represent a step-change in how autoimmune diseases are diagnosed and treated. If you care about developments in autoimmune therapy, keep an eye on partnership announcements and upcoming clinical designs from ImmuPharma — this is one of those rare biotech stories that blends scientific curiosity, hard data re-evaluation, and the potential for genuine patient impact.

    31 min

Ratings & Reviews

3.4
out of 5
16 Ratings

About

Designed for Private - Retail Investors, bloggers, brokers, PR, listed companies to communicate on one information portal. Please note we are an unregulated website and will never give out advice. We are here to make investing a level playing field.

You Might Also Like